{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:06:59Z","timestamp":1793200019705,"version":"4.5.0"},"reference-count":45,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","award":["16LW0239K"],"award-info":[{"award-number":["16LW0239K"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017268","name":"Berlin Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pathsocjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pathology CR"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, with limited therapeutic options, few patients showing targetable molecular changes. New therapeutic strategies are necessary. Antibody\u2013drug conjugates (ADCs) have emerged as alternative therapeutic strategies across various cancer types. Herein, we analyze the expression and spatial heterogeneity (six cores per patients) of three ADC targets (c\u2010MET, NECTIN4, and TROP\u20102) in a cohort of 62 PDAC patients (1,116 tissue cores) and associate their levels with clinicopathological and genomic parameters, and the expression of immune checkpoints. c\u2010MET exhibited significantly higher expression at the tumor front versus tumor center, along with notable intratumoral heterogeneity. In contrast, NECTIN4 and TROP\u20102 displayed homogeneous expression patterns, with NECTIN4 being absent in approximately two\u2010thirds of cases, while TROP\u20102 showed consistently strong positivity across tumor regions (98% 3+). By simulating sampling sufficiency for reliable scoring, we observed that, for c\u2010MET, two tumor samples were sufficient to achieve a maximum score of 1+, while for higher scores (2+ and 3+), four samples were required. For NECTIN4, four samples were necessary to detect scores of 1+ and 2+. For TROP\u20102, for a 3+ score, just two samples were sufficient to reach the maximum score. c\u2010MET or TROP\u20102 expression scores were not associated with any clinicopathological parameters. In contrast, NECTIN4 expression showed an association with tumor grade. Correlations with immune checkpoints revealed that high TROP\u20102 expression was inversely correlated with PD\u2010L1 expression. For all three markers no significant differences in expression were found between\n                    <jats:italic>SMAD4<\/jats:italic>\n                    wild\u2010type and\n                    <jats:italic>SMAD4<\/jats:italic>\n                    \u2010mutated tumors, nor between\n                    <jats:italic>TP53<\/jats:italic>\n                    wild\u2010type and\n                    <jats:italic>TP53<\/jats:italic>\n                    \u2010mutated tumors. Furthermore, analysis of lymph node and distant (liver and peritoneal) metastases revealed significantly higher c\u2010MET and NECTIN4 expression in the metastatic setting. In conclusion, TROP\u20102 is highly expressed in most PDACs, independent of clinicopathological and genomic parameters, and inversely correlating with PD\u2010L1, making TROP\u20102 an ideal ADC target.\n                  <\/jats:p>","DOI":"10.1002\/2056-4538.70083","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T10:50:15Z","timestamp":1773658215000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Spatial heterogeneity of antibody\u2013drug conjugate targets in pancreatic ductal adenocarcinoma"],"prefix":"10.1002","volume":"12","author":[{"given":"Deema","family":"Sabtan","sequence":"first","affiliation":[{"name":"Institute of Pathology Charite, Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Lisa","family":"Eich","sequence":"additional","affiliation":[{"name":"Institute of Pathology Charite, Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Loch","sequence":"additional","affiliation":[{"name":"Department of Surgery Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julen Karl","family":"P\u00e9rez Zuschneid","sequence":"additional","affiliation":[{"name":"Institute of Pathology Charite, Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"M\u00f6bs","sequence":"additional","affiliation":[{"name":"Institute of Pathology Charite, Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"B\u00f6hme","sequence":"additional","affiliation":[{"name":"Institute of Pathology Charite, Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Klauschen","sequence":"additional","affiliation":[{"name":"Institute of Pathology Charite, Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin  Berlin Germany"},{"name":"German Cancer Consortium (DKTK) German Cancer Research Center (DKFZ), Partner Site Berlin  Heidelberg Germany"},{"name":"Berlin Institute of Health Charite, Universit\u00e4tsmedizin Berlin  Berlin Germany"},{"name":"Institute of Pathology Ludwig Maximilians University  Munich Germany"},{"name":"Cancer Consortium (DKTK) German Cancer Research Center (DKFZ), Munich Partner Site  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Horst","sequence":"additional","affiliation":[{"name":"Institute of Pathology Charite, Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin  Berlin Germany"},{"name":"German Cancer Consortium (DKTK) German Cancer Research Center (DKFZ), Partner Site Berlin  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5550-3516","authenticated-orcid":false,"given":"Mihnea P","family":"Dragomir","sequence":"additional","affiliation":[{"name":"Institute of Pathology Charite, Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin  Berlin Germany"},{"name":"German Cancer Consortium (DKTK) German Cancer Research Center (DKFZ), Partner Site Berlin  Heidelberg Germany"},{"name":"Berlin Institute of Health Charite, Universit\u00e4tsmedizin Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Dernbach","sequence":"additional","affiliation":[{"name":"Institute of Pathology Charite, Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin  Berlin Germany"},{"name":"Aignostics GmbH  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Schallenberg","sequence":"additional","affiliation":[{"name":"Institute of Pathology Charite, Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin  Berlin Germany"},{"name":"German Cancer Consortium (DKTK) German Cancer Research Center (DKFZ), Partner Site Berlin  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11030562","article-title":"Pancreatic ductal adenocarcinoma: epidemiology and risk factors","volume":"11","author":"Ushio J","year":"2021","journal-title":"Diagnostics"},{"key":"e_1_2_8_4_1","unstructured":"BlueBooksOnline. [Accessed January 20 2026]. Available from:https:\/\/tumourclassification.iarc.who.int\/chaptercontent\/31\/126."},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy T","year":"2018","journal-title":"N Engl J Med"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13046-023-02868-x","article-title":"Antibody drug conjugates: hitting the mark in pancreatic cancer?","volume":"42","author":"Wittwer NL","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.688377","article-title":"The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy","volume":"11","author":"Principe DR","year":"2021","journal-title":"Front Oncol"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","article-title":"Therapeutic developments in pancreatic cancer","volume":"21","author":"Hu ZI","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA\u2010approved antibody\u2013drug conjugates in human cancers","volume":"23","author":"Liu K","year":"2024","journal-title":"Mol Cancer"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2\u2010expressing solid tumors: primary results from the DESTINY\u2010PanTumor02 phase II trial","volume":"42","author":"Meric\u2010Bernstam F","year":"2024","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody\u2013drug conjugates","volume":"21","author":"Tsuchikama K","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5179182","article-title":"The emerging role of c\u2010met in carcinogenesis and clinical implications as a possible therapeutic target","volume":"2022","author":"Faiella A","year":"2022","journal-title":"J Oncol"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1007\/s13346-024-01564-3","article-title":"Progress of antibody\u2013drug conjugates (ADCs) targeting c\u2010Met in cancer therapy; insights from clinical and preclinical studies","volume":"14","author":"Mer AH","year":"2024","journal-title":"Drug Deliv Transl Res"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16051056","article-title":"Pancreatic cancer treatment targeting the HGF\/c\u2010MET pathway: the MEK inhibitor trametinib","volume":"16","author":"Kim J","year":"2024","journal-title":"Cancer"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","article-title":"The anti\u2010Nectin 4: a promising tumor cells target. A systematic review","volume":"21","author":"Bouleftour W","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles T","year":"2021","journal-title":"N Engl J Med"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/genesandcancer.40","article-title":"Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications","volume":"6","author":"Shvartsur A","year":"2015","journal-title":"Genes Cancer"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/sj.bjc.6604677","article-title":"High expression of TROP2 correlates with poor prognosis in pancreatic cancer","volume":"99","author":"Fong D","year":"2008","journal-title":"Br J Cancer"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1158\/1535-7163.MCT-24-0266","article-title":"Novel amanitin\u2010based antibody\u2013drug conjugates targeting TROP2 for the treatment of pancreatic cancer","volume":"24","author":"Papacharisi E","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-med-071322-065903","article-title":"Leveraging TROP2 antibody\u2010drug conjugates in solid tumors","volume":"75","author":"Nelson BE","year":"2024","journal-title":"Annu Rev Med"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot Y","year":"2019","journal-title":"N Engl J Med"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104657","article-title":"DNA methylation\u2010based classifier differentiates intrahepatic pancreato\u2010biliary tumours","volume":"93","author":"Dragomir MP","year":"2023","journal-title":"EBioMedicine"},{"key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13148-024-01768-x","article-title":"DNA methylation classifier to diagnose pancreatic ductal adenocarcinoma metastases from different anatomical sites","volume":"16","author":"Calina TG","year":"2024","journal-title":"Clin Epigenetics"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1080\/17501911.2025.2554571","article-title":"DNA methylation profile to aid in the diagnosis of pancreatic ductal adenocarcinoma and its role in disease progression","volume":"17","author":"Grafenhorst E","year":"2025","journal-title":"Epigenomics"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032160","article-title":"The immune checkpoint landscape in tumor cells of pancreatic ductal adenocarcinoma","volume":"24","author":"Loch FN","year":"2023","journal-title":"Int J Mol Sci"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100753","article-title":"Spatial expression of HER2, NECTIN4, and TROP\u20102 in muscle\u2010invasive bladder cancer and metastases: implications for pathological and clinical management","volume":"38","author":"Dernbach G","year":"2025","journal-title":"Mod Pathol"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jtho.2023.06.020","article-title":"MET fusions in NSCLC: clinicopathologic features and response to MET inhibition","volume":"19","author":"Riedel R","year":"2024","journal-title":"J Thorac Oncol"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody\u2010drug conjugate targeting nectin\u20104 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita\u2010Eid PM","year":"2016","journal-title":"Cancer Res"},{"key":"e_1_2_8_29_1","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.3390\/curroncol29060312","article-title":"Trop\u20102 in upper tract urothelial carcinoma","volume":"29","author":"Tomiyama E","year":"2022","journal-title":"Curr Oncol"},{"key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of nectin\u20104 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman\u2010Censits JH","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.12.006"},{"key":"e_1_2_8_32_1","doi-asserted-by":"crossref","first-page":"73098","DOI":"10.18632\/oncotarget.20392","article-title":"Prognostic value of c\u2010Met overexpression in pancreatic adenocarcinoma: a meta\u2010analysis","volume":"8","author":"Kim JH","year":"2017","journal-title":"Oncotarget"},{"key":"e_1_2_8_33_1","doi-asserted-by":"crossref","first-page":"11361","DOI":"10.1038\/s41598-024-62031-0","article-title":"Topographic analysis of pancreatic cancer by TMA and digital spatial profiling reveals biological complexity with potential therapeutic implications","volume":"14","author":"Bingham V","year":"2024","journal-title":"Sci Rep"},{"key":"e_1_2_8_34_1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/his.12691","article-title":"High c\u2010Met expression in stage I\u2013II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis","volume":"67","author":"Neuzillet C","year":"2015","journal-title":"Histopathology"},{"key":"e_1_2_8_35_1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00109-022-02179-2","article-title":"c\u2010Met up\u2010regulates the expression of PD\u2010L1 through MAPK\/NF\u2010\u03baBp65 pathway","volume":"100","author":"Xu R","year":"2022","journal-title":"J Mol Med"},{"key":"e_1_2_8_36_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13046-015-0144-7","article-title":"Nectin\u20104 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer","volume":"34","author":"Nishiwada S","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"e_1_2_8_37_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113379","article-title":"Pan\u2010cancer analysis of antibody\u2010drug conjugate targets and putative predictors of treatment response","volume":"195","author":"Bosi C","year":"2023","journal-title":"Eur J Cancer"},{"key":"e_1_2_8_38_1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1369\/0022155411410430","article-title":"Expression of Trop2 cell surface glycoprotein in normal and tumor tissues","volume":"59","author":"Stepan LP","year":"2011","journal-title":"J Histochem Cytochem"},{"key":"e_1_2_8_39_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102108","article-title":"Trop\u20102 is a ubiquitous and promising target in pancreatic adenocarcinoma","volume":"47","author":"Mas L","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"e_1_2_8_40_1","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/1078-0432.CCR-23-2566","article-title":"TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non\u2010small cell lung cancer","volume":"30","author":"Bessede A","year":"2024","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_41_1","doi-asserted-by":"crossref","unstructured":"WuB ThantW BitmanE et al.A TROP2\/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer. bioRxiv2024; 2024.12.02.626446.","DOI":"10.1101\/2024.12.02.626446"},{"key":"e_1_2_8_42_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01878","article-title":"Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options","volume":"9","author":"Kabacaoglu D","year":"2018","journal-title":"Front Immunol"},{"key":"e_1_2_8_43_1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.euf.2024.04.001","article-title":"Biomarkers of response to anti\u2010NECTIN4 antibody\u2010drug conjugate enfortumab vedotin in urothelial cancer","volume":"10","author":"Kl\u00fcmper N","year":"2024","journal-title":"Eur Urol Focus"},{"key":"e_1_2_8_44_1","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti\u2010programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg JE","year":"2019","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_45_1","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1158\/1078-0432.CCR-22-3882","article-title":"Scratching the surface: NECTIN\u20104 as a surrogate for enfortumab vedotin resistance","volume":"29","author":"Aggen DH","year":"2023","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_46_1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2010drug conjugates come of age in oncology","volume":"22","author":"Dumontet C","year":"2023","journal-title":"Nat Rev Drug Discov"}],"container-title":["The Journal of Pathology: Clinical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pathsocjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/2056-4538.70083","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pathsocjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/2056-4538.70083","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pathsocjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/2056-4538.70083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T10:50:22Z","timestamp":1773658222000},"score":1,"resource":{"primary":{"URL":"https:\/\/pathsocjournals.onlinelibrary.wiley.com\/doi\/10.1002\/2056-4538.70083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/2056-4538.70083"],"URL":"https:\/\/doi.org\/10.1002\/2056-4538.70083","archive":["Portico"],"relation":{},"ISSN":["2056-4538","2056-4538"],"issn-type":[{"value":"2056-4538","type":"print"},{"value":"2056-4538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70083"}}